Esters of bendamustine are by far more potent cytotoxic agents than the parent compound against human sarcoma and carcinoma cells

URN to cite this document:: urn:nbn:de:bvb:355-epub-312384
DOI to cite this document:: 10.5283/epub.31238

Huber, Stefan ; Huettner, Johannes Philip ; Hacker, Kristina ; Bernhardt, Günther ; König, Jörg ; Buschauer, Armin

Preview

PDF
(1MB)

Date of publication of this fulltext: 09 Jul 2015 08:11

Alternative links to fulltext:DOI Pubmed

Details

Preview

Export bibliographical data

Abstract

The alkylating agent bendamustine is approved for the treatment of hematopoietic malignancies such as non-Hodgkin lymphoma, chronic lymphocytic leukemia and multiple myeloma. As preliminary data on recently disclosed bendamustine esters suggested increased cytotoxicity, we investigated representative derivatives in more detail. Especially basic esters, which are positively charged under ...